Pfizer (PFE)
(Delayed Data from NYSE)
$23.49 USD
+0.20 (0.86%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $23.52 +0.03 (0.13%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PFE 23.49 +0.20(0.86%)
Will PFE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PFE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PFE
MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View
Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings
PFE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pfizer (PFE) Dips More Than Broader Market: What You Should Know
Microsoft Q4 Earnings & Revenues Beat on Cloud Business Expansion
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View
Other News for PFE
Walt Disney, McDonald's, Palantir Set To Report Earnings
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8.5% (August 2025)
Bristol-Myers Q2 Earnings Review: Solid Quarter, But Incoming CMO Must Fix Pipeline
Market Voices: Trump vs. Big Pharma, Swiss tariffs, tariff legality
Experts helping vaccine advisors are reportedly ousted at CDC